DOCSLIB.ORG

Materializing Estrogen and Regulation Under Canada's Food and Drugs Act, 1939-1953 Lara Jessie Tessaro

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Materializing Estrogen and Regulation Under Canada's Food and Drugs Act, 1939-1953 Lara Jessie Tessaro Osgoode Hall Law School of York University Osgoode Digital Commons LLM Theses Theses and Dissertations 8-27-2018 Toxic Enactments: Materializing Estrogen and Regulation Under Canada's Food and Drugs Act, 1939-1953 Lara Jessie Tessaro Follow this and additional works at: https://digitalcommons.osgoode.yorku.ca/llm Part of the Legal History Commons TOXIC ENACTMENTS: MATERIALIZING ESTROGEN AND REGULATION UNDER CANADA’S FOOD AND DRUGS ACT, 1939-1953 LARA TESSARO A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF LAWS GRADUATE PROGRAM IN LAW OSGOODE HALL LAW SCHOOL, YORK UNIVERSITY TORONTO, ONTARIO August 2018 © Lara Tessaro, 2018 ABSTRACT The study describes how estrogen was standardized in Canada, in the 1940s and early 1950s, under the Food and Drugs Act. Contributing to interdisciplinary conversations, it provides an empirical case of how regulatory practices enact material realities. Using archival material, the study describes how estrogen was achieved, in part, through heterogeneous practices of the Canadian Committee on Pharmacopoeial Standards, National Health, and government solicitors. These regulators disagreed on whether, how, and by whom estrogens should be standardized. Rather than resolve these disagreements, Canada enacted multiple regulations purporting to standardize estrogen, and government solicitors practiced “techniques of validating” to render the regulations as lawful. I argue that these regulatory enactments materialized estrogen as a potent, unpredictable, and multiple object. Further, I show how estrogen spawned novel regulatory techniques in Canada, particularly the use of consumer product labels. In this way, estrogen catalyzed an early example of risk regulation in Canada. ii ACKNOWLEDGEMENTS First and foremost, I acknowledge my co-supervisors, Dr. Dayna Nadine Scott and Dr. Roxanne Mykitiuk, for their guidance, mentorship, care, and many hours of labour. Dayna steered me early on towards STS and historical scholarship that proved important to this project. She has helped me throughout to sharpen and expand my thinking about toxicity and law. However, her mentorship has extended well beyond the thesis. She ensured that I had the chance to try my hand at lecturing and delivering seminars, invited me to participate in academic events, and opened doors at the Law and Society Association conference, giving me useful and direct feedback throughout. In low-key conversations, she helped me to enculturate, sharing insights into academic practices, norms, funding, publishing. Always unapologetically political, Dayna has modelled – in word and deed – what it means to be a feminist scholar. Roxanne mentored with kindness and patience. It has not been easy to shake off lawyerly practices, among others “writing like a lawyer”. Roxanne always attended to the quality of my writing, and I am grateful for her close reading of draft presentations and chapters. In the early days of this project, as I groped towards an argument, she would let me “think aloud” in her office. Being able to ramble through my overexcited and inchoate ideas with Roxanne was such a privilege, and it boosted my confidence after so many years away from academic spaces. Dayna and Roxanne also provided me with valuable opportunities to collaborate with them (and with Dr. Alana Cattapan and Dr. Jennie Haw) on CIHR-funded projects on toxics regulation. Dr. Elaine MacDonald, Margot Venton, and Professor Lynda Collins put much time and energy into supporting my funding applications. Their efforts were crucial. I remain very grateful. I began thinking about endocrine disruption as a staff lawyer at Ecojustice, when scheming up toxics projects with Elaine. In that capacity, I had the fortune of co-supervising Sally MacKinnon and Ian Arnold. I appreciate their efforts to help me start tracing estrogen’s legislative histories. Many people at Osgoode Hall Law School supported me during my LLM program. Dr. Stepan Wood invited me to be a Fellow with Osgoode’s Environmental Justice and Sustainability Clinic and, with Clinic Co-Director David Estrin, gave me opportunities to develop my teaching skills. After Stepan departed for more temperate climes, the new co-directors, Dr. Estair Van Wagner, Dr. Dayna Scott and David Estrin, continued that practice. Dr. Shelley Gavigan gifted me much time and wise counsel, from practical tips on archival research to galvanizing stories that let me glimpse the possibility of academia after practice. Research librarian Sharon Wang fielded innumerous questions. With inspired searches, Professor John Davis located a key regulation hidden in the Canada Gazettes, and gave cheery encouragement. Professors Ruth Buchanan and Cynthia Williams gently reintroduced me to learning in a classroom and granted meaningful accommodations when my mom was hospitalized. Professor Sonia Lawrence, with good humour and remarkable persistence, helped with everything: navigating guidelines, puzzling through ethical questions, pondering copyright, signing so many forms. Staff in the Graduate Program Office, including Heather Moore and Chantel Thompson, provided frequent help. iii At York University, Dr. Miriam Smith and Dr. Kean Birch kindly let me audit their graduate courses in law and social theory, and science and technology studies, respectively. I am grateful to them, and to my classmates in those courses, for helping me learn how to think again. Dr. Jim Phillips and Dr. Philip Girard welcomed me into the Osgoode Hall Legal History Workshop. They provided me with a truly marvelous opportunity to workshop an early version of Chapter Four, and the workshop participants provided generous and insightful suggestions. This project also benefitted from valuable feedback at the Canadian Science and Technology Historical Association’s biennial conference, the Technologies of Justice Conference organized by the University of Ontario Institute of Technology and the Canadian Law and Society Association, and the Institute for History and Philosophy of Science and Technology’s 50th Anniversary Conference. I extend appreciation to the conference organizers and participants. At Library and Archives Canada, archivists and other staff contributed expert and timely assistance. I also thank the talented investigators at the Office of the Information Commissioner. A number of organizations provided generous financial support for this research. I could never have pursed this degree without the support of the Law Foundation of British Columbia Graduate Fellowship, the Honourable William Z. Estey Graduate Fellowship in Law (supported by Osgoode Hall), the Ontario Graduate Scholarship, and the York Graduate Scholarship. Friends and colleagues were willing to engage with my ideas about hormones, cosmetics, law, and history, in brief intense sessions or in ongoing conversations. My thanks to Danielle Allen, Deb Casey, Sandra Ka Hon Chu, Pierre Cloutier de Repentigny, Alexandra Dosman, Julie Falck, Lana Hanna, Megan Howatt, Else Knudsen, Gitanjali Lena, Sylvie Prud’homme, Simon Routh, Risa Schwartz, Tess Sheldon, and Maggie Wente. Shadowy members of The Chemical Castration allowed me to keep in sight the toxic present whilst playing in the hormonal past. In Vancouver, Colleen Fulton, Jason Gratl, Susan Howatt, Susan Pinkus, and Sarah Townsend likewise entertained and refined my ideas – though admittedly they were captive audiences. In housing me at short notice, at various times in the last two years, they made difficult moments much easier. For nourishing me while I invaded your establishments with my Machinetta and books: merci à Le Baratin (what I wrote), the Federal (what I wrote about), and the Wallflower (what I became). For more-than-human companionship while I was writing: Joey, Moses (Mossimo), Taco. Lana, Clarke, Lola, and Emeline Hanna gave me a home away from home, and turned my own wee nest into a much more exciting place. But for the gastroenteritis, I treasured every moment. Gratitude and love to Judy Tessaro, Mark Tessaro, Leslie Summers deLuca, Matilda Tessaro, and Fern Summers. iv TABLE OF CONTENTS Abstract ii Acknowledgments iii Table of Contents v List of Figures vi PART I 1 An introduction 1 Chapter One: History and theory: toxic enactments 10 Section 1: Sex hormones and drug standardization in the 1930s-1940s 11 1.i. Sex hormones on the edge of transformation 11 1.ii. Standardization of biological drugs in the mid-twentieth century 19 Section 2: Theoretical literatures on enactment 27 2.i. Annemarie Mol and the enactment of multiple ontologies 27 2.ii. Enactment and the sociology of standards 35 2.iii. Enactment in interdisciplinary legal studies 37 Chapter Two: Legal history, in theory: historical approach and research methods 43 Section 1: An historical approach – but, to what? 43 Section 2: Research methods – or, how practices enact realities 46 PART II Chapter Three: Delegating standards, assembling regulators: new ways of regulating drugs in Canada at the start of the 1940s 52 Section 1: Delegation and standard-setting under the Food and Drugs Act prior to 1940 55 Section 2: The formation of the Canadian Committee on Pharmacopoeial Standards, 1940-1942 73 Chapter Four: “At some loss as to the precise object you have in mind”: enacting estrogen multiply, 1943-1944 91 Section 1: The Committee attempts to standardize estrogen, 1943 93 1.i. “Canadian Standards should specify methods of assay around which everything seemed to centre”: the Committee meets, January 1943
Load more

Recommended publications
  • Clomifene Citrate(BANM, Rinnm) ⊗
    2086 Sex Hormones and their Modulators Profasi; UK: Choragon; Ovitrelle; Pregnyl; USA: Chorex†; Choron; Gonic; who received the drug for a shorter period.6 No association be- 8. Werler MM, et al. Ovulation induction and risk of neural tube Novarel; Ovidrel; Pregnyl; Profasi; Venez.: Ovidrel; Pregnyl; Profasi†. tween gonadotrophin therapy and ovarian cancer was noted in defects. Lancet 1994; 344: 445–6. Multi-ingredient: Ger.: NeyNormin N (Revitorgan-Dilutionen N Nr this study. The conclusions of this study were only tentative, 9. Greenland S, Ackerman DL. Clomiphene citrate and neural tube 65)†; Mex.: Gonakor. defects: a pooled analysis of controlled epidemiologic studies since the numbers who developed ovarian cancer were small; it and recommendations for future studies. Fertil Steril 1995; 64: has been pointed out that a successfully achieved pregnancy may 936–41. reduce the risk of some other cancers, and that the risks and ben- 10. Whiteman D, et al. Reproductive factors, subfertility, and risk efits of the procedure are not easy to balance.7 A review8 of epi- of neural tube defects: a case-control study based on the Oxford Clomifene Citrate (BANM, rINNM) ⊗ Record Linkage Study Register. Am J Epidemiol 2000; 152: demiological and cohort studies concluded that clomifene was 823–8. Chloramiphene Citrate; Citrato de clomifeno; Clomifène, citrate not associated with any increase in the risk of ovarian cancer 11. Sørensen HT, et al. Use of clomifene during early pregnancy de; Clomifeni citras; Clomiphene Citrate (USAN); Klomifeenisi- when used for less than 12 cycles, but noted conflicting results, and risk of hypospadias: population based case-control study.
    [Show full text]
  • Proceedings of the Thirtieth Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N
    PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 J Clin Invest. 1938;17(4):501-537. https://doi.org/10.1172/JCI100977. Research Article Find the latest version: https://jci.me/100977/pdf PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 READ BEFORE THE SCIENTIFIC SESSION The Successful Treatment of Pernicious Anemia by in powdered form hemostasis was readily obtained in Means of Non-Autolyzed Yeast. By MAXWELL M. hemorrhages following nine dental extractions and three WINTROBE, Baltimore, Md. external wounds in five hemophilic subjects. When ap- It has been the general opinion that yeast, if it pos- plied in liquid form as other hemostatics are usually em- sesses any antianemic potency whatever, is effective only 1 loyed the results were unsatisfactory. Since the co- after autolysis and then only by virtue of its content of agulation time of the circulating blood was unchanged the "extrinsic factor." The observations reported contradict effectiveness of powdered beef globulin substance when this view and indicate that dehydrated yeast which has locally applied to a bleeding wound in hemophilia is not been subjected to autolysis, contains an antiper- attributed to the rapid formation of a firm fibrin clot. nicious anemia substance. Yeast obtained from two dif- The failure of liquid preparations may be due to the ferent sources was effective in the treatment of classical inability to maintain a sufficient concentration of the cases of pernicious anemia.
    [Show full text]
  • Chemical Compounds As Carcinogenic Agents Second Supplementary Report: Literature of 1938 and 1939 Biological Considerations
    CHEMICAL COMPOUNDS AS CARCINOGENIC AGENTS SECONDSUPPLEMENTARY REPORT: LITERATURE OF 1938 AND 1939 J. W. COOK AND E. L. KENNAWAY (From the Royal Cancer Hospital (Free), London, and the University of Glasgow) BIOLOGICALCONSIDERATIONS (Continued from page 428, Jitly 1940) II. Action of Carcinogenic Compounds in Difierent Species and Tissues A number of reports of the action of carcinogenic compounds on human tis- sues have appeared. Klar (601) developed a nodule on the forearm after completion of a series of experiments with 3:4-benzpyrene. He applied a solution of the hydrocarbon (0.25 per cent in benzol) to the skin of mice with a paint brush and for at least part of the period wore rubber gloves. He also conducted experiments, of which no description is given, with the powdered hydrocarbon contained in a glass vessel. Three months after the completion of the experiments a small nodule appeared on the dorsum of the left forearm, This was excised in May 1938 and described by Professor Huckel as a “ so- called benign calcifying epithelioma.” The growth extended into the subcu- taneous fatty tissue; the connection with the superficial epithelium is not described nor is it evident in the two photomicrographs which illustrate the report. The author does not state his age. Gordonoff and Walthard (562) record the occurrence of a tumor in a labo- ratory assistant, aged forty-two, engaged in applying methylcholanthrene (0.3 per cent in benzol) to the skin of mice. The site was in the nasolabial fold, at a spot often touched by the patient when smoking. The microscopic ap- pearance was that of a “ still well delimited stage of an incipient squamous- cell sarcoma.” Cottini and Mazzone (479) deliberately applied 3 :4-benzpyrene ( 1 per cent in benzene) to the skin, generally of the arm or thigh, of 26 patients with various cutaneous diseases, usually daily for periods up to 120 days.
    [Show full text]
  • The Reactivity of Human and Equine Estrogen Quinones Towards Purine Nucleosides
    S S symmetry Article The Reactivity of Human and Equine Estrogen Quinones towards Purine Nucleosides Zsolt Benedek †, Peter Girnt † and Julianna Olah * Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Szent Gellért tér 4, H-1111 Budapest, Hungary; [email protected] (Z.B.); [email protected] (P.G.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Conjugated estrogen medicines, which are produced from the urine of pregnant mares for the purpose of menopausal hormone replacement therapy (HRT), contain the sulfate conjugates of estrone, equilin, and equilenin in varying proportions. The latter three steroid sex hormones are highly similar in molecular structure as they only differ in the degree of unsaturation of the sterane ring “B”: the cyclohexene ring in estrone (which is naturally present in both humans and horses) is replaced by more symmetrical cyclohexadiene and benzene rings in the horse-specific (“equine”) hormones equilin and equilenin, respectively. Though the structure of ring “B” has only moderate influence on the estrogenic activity desired in HRT, it might still significantly affect the reactivity in potential carcinogenic pathways. In the present theoretical study, we focus on the interaction of estrogen orthoquinones, formed upon metabolic oxidation of estrogens in breast cells with purine nucleosides. This multistep process results in a purine base loss in the DNA chain (depurination) and the formation of a “depurinating adduct” from the quinone and the base. The point mutations induced in this manner are suggested to manifest in breast cancer development in the long run.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
    PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28
    [Show full text]
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • Estriol Prevention of Mammary Carcinoma Induced by 7,12-Dimethylbenzanthracene and Procarbazine1
    (CANCER RESEARCH 35, 1341 1353, May 1975] Estriol Prevention of Mammary Carcinoma Induced by 7,12-Dimethylbenzanthracene and Procarbazine1 Henry M. Lemon Section of Oncology, Department of Internal Medicine, The University of Nebraska Medical Center, 42nd Street and Dewey Avenue, Omaha. Nebraska 68105 SUMMARY hexestrol, 0.60 mg/pellet, did not alter breast cancer incidence in 220 additional rats. Estrogen-treated rats The concentration of estrogenic, androgenic, progesta- usually sustained a mean 0.6 to 8.9% reduction of body tional, and adrenocortical steroid hormones in body fluids growth for the first 6 to 8 months of observation; this did of mature intact Sprague-Dawley female rats was increased not correlate with the breast carcinoma-suppressive activi by s.c. implantation of 5 to 7 mg NaCl pellets containing 1 ties of individual steroids. to 20% steroid 48 hr before administration p.o. of either Single implantation of 0.60 mg estriol 48 hr before 7,12-dimethylbenz(a)anthracene or procarbazine. The inci dimethylbenzanthracene p.o. or sustained implantation dence of rats developing one or more mammary carcinomas every 2 months of 10% estriol pellets beginning 24 hr after in each treated group was compared to that observed in si carcinogen exposure failed significantly to alter mammary multaneously treated groups receiving only the carcinogen, carcinoma development after dimethylben/anthracene ad steroid, or no treatment whatsoever, with weekly observa ministration. tion of all rats until palpably growing tumors were biopsied Inhibition of mammary carcinogenesis induced by these and proven carcinomatous or until death occurred from two dissimilar carcinogens in intact mature rats using other causes determined by autopsy.
    [Show full text]
  • Patent Office
    UNITED STATES 2,233,025PATENT OFFICE ESTRADIO-1-MONOESTERS Karl Miescher, Riehen, and Caesar Scholz, Basel, Switzerland, assignors, by mesne assignments, to Ciba, Pharmaceutical Products, Incorporated, Summit, N.J., a corporation of New Jersey No Drawing. Application October 7, 1937, Serial No. 167,866. In Switzerland November 20, 1936 4 Claims. (CI. 260-397) This invention is based on the surprising ob servation that partially esterified compounds of ually passes into solution. This solution is acidi the dihydro-estrin series having a free phenolic fied and a precipitate is produced by the addi hydroxyl are obtained when completely esterified tion of 200 parts of water. This is filtered and 5 compounds of the dihydro-estrin series are treat Washed Successively with water, dilute sodium ed in careful manner with hydrolytically acting carbonate Solution and again with water. The agents. In this way only those acid residues are estradiol-17-mono-propionate which is already split off which are bound at the phenolic hy Very pure can be recrystallized from a mixture O droxyl-groups. of methyl alcohol and water. It melts at As hydrolytically acting agents there may be 199-200° C. used both those of an alkaline nature and those The time necessary for the reaction depends of an acid nature. Suitable alkaline agents are, on the temperature and the degree of dilution for example alkali hydroxides, alkali carbonates, used. 5. alkaline earth hydroxides, magnesia or the like. Eacample 2 As acid reagents hydrogen halide acids, Sulfuric A solution of 1 part of estradiol-3:17-dipro acid, phosphoric acid or the like may be used.
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • The Rabbits Are Prepared ..." - the Development of Ethinylestradiol and Ethinyltestosterone Frobenius W J
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie "The Rabbits are Prepared ..." - The Development of Ethinylestradiol and Ethinyltestosterone Frobenius W J. Reproduktionsmed. Endokrinol 2011; 8 (Sonderheft 1), 32-57 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Development of Ethinylestradiol and Ethinyltestosterone “The Rabbits are Prepared …” – The Development of Ethinylestradiol and Ethinyltestosterone W. Frobenius In an exciting scientific neck-and-neck race, European and American scientists in the late 1920s and early 1930s isolated the ovarian, placental, and testicular hormones. At the same time the constitution of the human sex steroids was elucidated. However, it soon emerged that with oral administration the therapeutic value of the natural substances was extremely limited.
    [Show full text]
  • Antiviral Drug
    Suraj Punj Journal For Multidisciplinary Research ISSN NO: 2394-2886 Vibrational spectra of 1- methylestin-3 thosomicarbozole (methisazole): Antiviral Drug Dr. DB Singh*, Kiran Pandey, Pragya Singh, Deepali Singh, Madhusmita Singh, DEEPIKA NISHAD Micro molecular and Bio physics Laboratory; Department Of Physics; DSMNR University; Lucknow. Abstract: 1-methylestin-3 thosomicarbozole (methisazole) is a chemical compound that shows the property of Antiviral Drug. A complete assignment of fundamental vibration frequencies has been made, and the spectra have been interpreted in detail. The non-planar frequencies have been calculated with the aid of force constants determined for related molecules. The fundamental vibrational frequencies and intensity of vibrational bands were evaluated using density functional theory (DFT) using standard B3LYP/6-31G methods and basis set combinations. The optimized geometric structure of 1- methylestin-3 thosomicarbozole (methisazole) has been studied by using Density Functional Theory (DFT). On the basis of ground and excited state geometries, the absorption spectra have been calculated using the DFT method. To understand the Non-Linear Optical properties of 1- methylestin-3 thosomicarbozole (methisazole), we computed dipole moment (μ) ,using B3LYP density functional theory method in conjunction with 6-31G basis set. Keywords: FTIR, FT-Raman, DFT, HOMO, LUMO, Vibrational spectra, antiviral. Volume 9, Issue 4, 2019 Page No: 31 Suraj Punj Journal For Multidisciplinary Research ISSN NO: 2394-2886 Introduction: 1-methylestin-3 thosomicarbozole (methisazole) is a chemical compound that shows the property of Antiviral Drug. The optimized geometrical compound of antiviral activity, this antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled.
    [Show full text]